GlobeNewswire
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
➖
AI Sentiment
Neutral
5/10
Reviva Pharmaceuticals Holdings Inc. News
Latest updates and market news for RVPH
1 news
Dec 23 - Dec 29, 2025
Page 1
Share this news page